Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?

This observational study aims to evaluate the efficacy of naloxegol therapy in resolving opioid-induced constipation (OIC) and in improving the quality of life in a home palliative care cancer setting. Advanced cancer patients with OIC (Rome IV criteria) not relieved by laxatives started a naloxegol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rita Ostan, Giuseppe Gambino, Italo Malavasi, Gianluca Ronga, Maria Solipaca, Michela Spunghi, Silvia Varani, Raffaella Pannuti, Enrico Ruggeri
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cancer naloxegol opioid-induced constipation palliative care antagonists opioid receptor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a34d436417a34bf281e66994b852fbd0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a34d436417a34bf281e66994b852fbd0
record_format	dspace
spelling	oai:doaj.org-article:a34d436417a34bf281e66994b852fbd02021-11-25T17:03:24ZCan Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?10.3390/cancers132257362072-6694https://doaj.org/article/a34d436417a34bf281e66994b852fbd02021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5736https://doaj.org/toc/2072-6694This observational study aims to evaluate the efficacy of naloxegol therapy in resolving opioid-induced constipation (OIC) and in improving the quality of life in a home palliative care cancer setting. Advanced cancer patients with OIC (Rome IV criteria) not relieved by laxatives started a naloxegol therapy 25 mg/day for 4 weeks. Quality of life was evaluated by Patient Assessment of Constipation Quality-of-Life (PAC-QoL) at day 0 and day 28; background pain by Numerical Rating Scale, number of weekly spontaneous bowel movements and Bowel Function Index (BFI) were evaluated at day 0 and every week. Seventy-eight patients who completed the 4-week study improved all four PAC-QoL dimensions (physical and psychological discomfort, worries/concerns and satisfaction level). Weekly spontaneous bowel movements increased and BFI improved. Background pain reduced after seven days and remained lower during the following weeks. Seventy-two patients dropped out the study before day 28 with a reduced survival compared to patients completing the study. Even in these patients, an improvement of bowel function was observed after two weeks. Naloxegol was effective in improving the quality of life, resolving OIC and reducing overall pain in patients with advanced cancer.Rita OstanGiuseppe GambinoItalo MalavasiGianluca RongaMaria SolipacaMichela SpunghiSilvia VaraniRaffaella PannutiEnrico RuggeriMDPI AGarticlecancernaloxegolopioid-induced constipationpalliative careantagonistsopioid receptorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5736, p 5736 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer naloxegol opioid-induced constipation palliative care antagonists opioid receptor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cancer naloxegol opioid-induced constipation palliative care antagonists opioid receptor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Rita Ostan Giuseppe Gambino Italo Malavasi Gianluca Ronga Maria Solipaca Michela Spunghi Silvia Varani Raffaella Pannuti Enrico Ruggeri Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
description	This observational study aims to evaluate the efficacy of naloxegol therapy in resolving opioid-induced constipation (OIC) and in improving the quality of life in a home palliative care cancer setting. Advanced cancer patients with OIC (Rome IV criteria) not relieved by laxatives started a naloxegol therapy 25 mg/day for 4 weeks. Quality of life was evaluated by Patient Assessment of Constipation Quality-of-Life (PAC-QoL) at day 0 and day 28; background pain by Numerical Rating Scale, number of weekly spontaneous bowel movements and Bowel Function Index (BFI) were evaluated at day 0 and every week. Seventy-eight patients who completed the 4-week study improved all four PAC-QoL dimensions (physical and psychological discomfort, worries/concerns and satisfaction level). Weekly spontaneous bowel movements increased and BFI improved. Background pain reduced after seven days and remained lower during the following weeks. Seventy-two patients dropped out the study before day 28 with a reduced survival compared to patients completing the study. Even in these patients, an improvement of bowel function was observed after two weeks. Naloxegol was effective in improving the quality of life, resolving OIC and reducing overall pain in patients with advanced cancer.
format	article
author	Rita Ostan Giuseppe Gambino Italo Malavasi Gianluca Ronga Maria Solipaca Michela Spunghi Silvia Varani Raffaella Pannuti Enrico Ruggeri
author_facet	Rita Ostan Giuseppe Gambino Italo Malavasi Gianluca Ronga Maria Solipaca Michela Spunghi Silvia Varani Raffaella Pannuti Enrico Ruggeri
author_sort	Rita Ostan
title	Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_short	Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_full	Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_fullStr	Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_full_unstemmed	Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_sort	can naloxegol therapy improve quality of life in patients with advanced cancer?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a34d436417a34bf281e66994b852fbd0
work_keys_str_mv	AT ritaostan cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT giuseppegambino cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT italomalavasi cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT gianlucaronga cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT mariasolipaca cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT michelaspunghi cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT silviavarani cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT raffaellapannuti cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer AT enricoruggeri cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
_version_	1718412793391087616

Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?

Ejemplares similares